1. Nano co-delivery of doxorubicin and plumbagin achieves synergistic chemotherapy of hepatocellular carcinoma.
- Author
-
Cao C, Li Y, Shi F, Jiang S, Li Y, Yang L, Zhou X, Gao Y, Tang F, Li H, Han S, Yu Z, Zou Y, and Guo J
- Subjects
- Animals, Humans, Polyethylene Glycols chemistry, Polyethylene Glycols administration & dosage, Mice, Inbred BALB C, Polylactic Acid-Polyglycolic Acid Copolymer chemistry, STAT3 Transcription Factor metabolism, STAT3 Transcription Factor antagonists & inhibitors, Cell Line, Tumor, Mice, Nanoparticles chemistry, Drug Resistance, Neoplasm drug effects, Nanoparticle Drug Delivery System chemistry, Mice, Nude, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic pharmacology, Male, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols pharmacology, Doxorubicin administration & dosage, Doxorubicin pharmacology, Doxorubicin chemistry, Naphthoquinones administration & dosage, Naphthoquinones chemistry, Naphthoquinones pharmacology, Carcinoma, Hepatocellular drug therapy, Liver Neoplasms drug therapy, Drug Synergism
- Abstract
Doxorubicin (DOX) is a chemotherapy drug used for hepatocellular carcinoma (HCC) treatment, but its effectiveness can be dramatically dampened by cancer cell chemoresistance. Signal transducer and activator of transcription 3 (STAT3) is implicated with drug resistance in a range of cancers (e.g., HCC), and the STAT3 inhibition can reverse the resistance of cancer cells to chemotherapeutic drugs. In the present study, a combination regimen to improve the efficiency of DOX was provided via the STAT3 blockade using plumbagin (PLB). A poly(lactic-co-glycolic acid) decorated by polyethylene glycol and aminoethyl anisamide was produced in the present study with the hope of generating the nanoparticles for co-delivery of DOX and PLB. The resulting co-formulation suppressed the STAT3 activity and achieved the synergistic chemotherapy, which led to tumor inhibition in the mice with subcutaneous DOX-resistant HCC, without causing any toxicity. The present study reveals the synergism of DOX and PLB, and demonstrates a promising combinatorial approach for treating HCC., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Shulan Han reports financial support was provided by Jilin Provincial Science and Technology Department. Zhuo Yu reports financial support was provided by National Natural Science Foundation of China. Jianfeng Guo reports financial support was provided by Jilin Provincial Science and Technology Department. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF